Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers

[1]  Ludwig Kappos,et al.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[2]  Ludwig Kappos,et al.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[3]  H. Hartung,et al.  Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis , 2010, Clinical neuropharmacology.

[4]  X. Montalban,et al.  Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results , 2010, Multiple sclerosis.

[5]  V. Brinkmann.  FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system , 2009, British journal of pharmacology.

[6]  X. Montalban,et al.  Oral fingolimod (FTY720) in multiple sclerosis , 2009, Neurology.

[7]  L. Kappos,et al.  FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis , 2008, Neurology.

[8]  J. Kovarik,et al.  Oral‐intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects , 2007, Biopharmaceutics & drug disposition.

[9]  M. Kondo,et al.  Sphingosine 1-Phosphate Causes Airway Hyper-Reactivity by Rho-Mediated Myosin Phosphatase Inactivation , 2007, Journal of Pharmacology and Experimental Therapeutics.

[10]  V. Brinkmann,et al.  FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs. , 2006, International immunopharmacology.

[11]  Ludwig Kappos,et al.  Oral fingolimod (FTY720) for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[12]  J. Kovarik,et al.  FTY720: Placebo‐Controlled Study of the Effect on Cardiac Rate and Rhythm in Healthy Subjects , 2006, Journal of clinical pharmacology.

[13]  V. Brinkmann,et al.  Pulmonary and vascular pharmacology of sphingosine 1-phosphate. , 2006, Current opinion in pharmacology.

[14]  E. Frohman,et al.  Multiple sclerosis--the plaque and its pathogenesis. , 2006, The New England journal of medicine.

[15]  V. Brinkmann,et al.  The Heart Rate Decrease Caused by Acute FTY720 Administration Is Mediated by the G Protein‐Gated Potassium Channel IKACh , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[16]  J. Kovarik,et al.  Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects. , 2004, British journal of clinical pharmacology.

[17]  R. Zinkernagel,et al.  FTY720 Immunosuppression Impairs Effector T Cell Peripheral Homing Without Affecting Induction, Expansion, and Memory1 , 2000, The Journal of Immunology.